ICONOTIDE (FORMERLY SNX-111, Neurex Pharmaceuticals, Menlo Park, Calif) is the synthetic equivalent of-conopeptide MVIIA, a 25-amino-acid polybasic peptide present in the venom of Conus magus, a marine snail. 1 Ziconotide produces potent antinociceptive effects 2 by selectively binding to N-type voltage-sensitive calcium channels 3,4 on neuronal somata, dendrites, dendritic shafts, and axon terminals, thus blocking neurotransmission from primary nociceptive afferents. Ziconotide is the first selective Ntype voltage-sensitive calcium channel blocking agent to be tested in clinical trials. There is no evidence of tolerance to ziconotide 5 or of addictive behavior in animals (Elan Pharmaceuticals Inc, unpublished data), and the drug must be administered intrathecally to maximize antinociceptive effectiveness and minimize sympatholysis. 6
IDDSs improved clinical success in pain control, reduced pain, significantly relieved common drug toxicities, and improved survival in patients with refractory cancer pain.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.